1. Scrip
  2. >>Business

One To Watch: Chi-Med Approaches Inflection Points

 
• By Eleanor Malone

Hutchison China MediTech, or Chi-Med, will report pivotal or proof of concept data for savolitinib, fruquintinib and two other tyrosine kinase inhibitor candidates by Q1 2017. Having built a global cancer and inflammation R&D pipeline on the back of what started out 16 years ago as a domestic commercial botanicals business based in China, Chi-Med is now one to watch.

ChiMedHQBuilding_1200x675
Chi-Med facility • Source: Chi-Med

Hutchison China MediTech Ltd., better known as Chi-Med, is uniquely positioned as a global pharma R&D company based in China, supported by a profitable domestic prescription and OTC drugs business, with listings on both London’s AIM market and Nasdaq. Led for 16 years by British CEO Christian Hogg, the firm counts AstraZeneca PLC and Eli Lilly & Co. as partners and has global ambitions for its R&D pipeline, built around selective kinase inhibitors for cancer and inflammatory indications.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

More from Scrip

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.